It’s not the ‘big boy play’ I’ve been talking about for the last month (still sitting on that one), but Emblem Marijuana (SAB.H) has been looming for many months now and is finally jumping into action.

Formerly Kindcann, Emblem is RTOing and currently in the tail end of a raise. They’re valuing it at $22.5 million, which is absurdly cheap compared to the established brands out there, and maybe only a little cheap compared to similarly sized plays.

But where this one comes into its own is with the guys running the show.

emblem biosChrist on a bike. Not only have you got a 15 year President and CEO of Purdue Pharma in there, you’ve got retail pharmacy knowledge, MMPR knowledge, biotech knowledge, you’ve also got $4.5 million invested personally between them.

I don’t have a deal with Emblem, but with the financing closing (shares are $0.75 with a six month hold), I figured you should know now, rather than later, because it’s a sweet deal.

To get in on that financing, contact Danny Brody at Emblem, 647-255-8106 ex 1810 or or Shane Parhar at Mackie Research, and 778-373-8075.

— Chris Parry

Written By:

Chris Parry

A multi-Webster Award winner for excellence in BC journalism, Parry is the founder and publisher of Equity.Guru, which he built with the specific plan to blend old school reporting with stock promotion, in a way that puts the emphasis on truth, high standards, and ethics. Parry is a veteran of TV, radio, and print, and consults with public companies to help them figure out their storylines, lay down achievable milestones, and improve their communication with shareholders, while also posting regular deep dive analysis of companies in the public spotlight.

More By This Author
Emblem Cannabis
0 0 votes
Article Rating
Notify of
Newest Most Voted
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x